BIBLIOGRAFIA Bibliografia Abe, K., Fukuda, K. and Tokui, T., 2004. Marginal involvement of pyroglutamyl aminopeptidase I in m<strong>eta</strong>bolism of thyrotropin-releasing hormone in rat brain. Biol Pharm Bull. 27, 1197-1201. Abe, K., Watanabe, N., Kosaka, T., Yamada, M., Tokui, T. and Ikeda, T., 2003. Hydrolysis of synthetic substrate, L-pyroglutamyl p-nitroanilide is catalyzed solely by pyroglutamyl aminopeptidase I in rat liver cytosol. Biol Pharm Bull. 26, 1528-1533. Aberg, M. A., Aberg, N. D., Hedbacker, H., Oscarsson, J. and Eriksson, P. S., 2000. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci. 20, 2896-2903. Aberg, M. A., Aberg, N. D., Palmer, T. D., Alborn, A. M., Carlsson-Skwirut, C., Bang, P., Rosengren, L. E., Olsson, T., Gage, F. H. and Eriksson, P. S., 2003. IGF-I has a direct proliferative effect in adult hippocampal progenitor cells. Mol Cell Neurosci. 24, 23-40. Achee, F. M., Gabay, S. and Tipton, K. F., 1977. Some aspects of monoamine oxidase activity in brain. Prog Neurobiol. 8, 325-348. Agrawal, H. C. and Himwich, W. A., 1987. Developmental Neuroblastology (ed. Thomas, C. C.), pp. 287-310. Himwich, W. A. ed, Springfield. Ahotupa, M., Mantyla, E., Peltola, V., Puntala, A. and Toivonen, H., 1992. Prooxidant effects of normobaric hyperoxia in rat tissues. Acta Physiol Scand. 145, 151-157. Akasu, M., Urata, H., Kinoshita, A., Sasaguri, M., Ideishi, M. and Arakawa, K., 1998. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 32, 514-520. Alba, F., Arenas, J. C. and Lopez, M. A., 1995. Comparison of soluble and membranebound pyroglutamyl peptidase I activities in rat brain tissues in the presence of detergents. Neuropeptides. 29, 103-107. Alba, F., Iribar, C., Ramirez, M. and Arenas, C., 1989. [A fluorimetric method for the determination of brain aminopeptidases]. Arch Neurobiol (Madr). 52, 169-173. Alper, G., Girgin, F. K., Ozgonul, M., Mentes, G. and Ersoz, B., 1999. MAO inhibitors and oxidant stress in aging brain tissue. Eur Neuropsychopharmacol. 9, 247- 252. Amenta, F., Spillantini, M. G., Cavallotti, C. and Geppetti, P., 1988. Increase in substance P levels in the lung of old rats. Arch Gerontol Geriatr. 7, 215-219. Angevine, J. B., Jr., 1965. Time of neuron origin in the hippocampal region. An autoradiographic study in the mouse. Exp Neurol, Suppl 2:1-70. Ansari, M. A., Demello, D. E., Polk, D. H. and Devaskar, U. P., 1997. Thyrotropinreleasing hormone accelerates f<strong>eta</strong>l mouse lung ultrastructural maturation via stimulation of extra thyroidal pathway. Pediatr Res. 42, 709-714. Bibliografia 217
Bibliografia Aoyagi, T., Hatsu, M., Imada, C., Naganawa, H., Okami, Y. and Takeuchi, T., 1992a. Pyrizinostatin: a new inhibitor of pyroglutamyl peptidase. J Antibiot (Tokyo). 45, 1795-1796. Aoyagi, T., Hatsu, M., Kojima, F., Hayashi, C., Hamada, M. and Takeuchi, T., 1992b. Benarthin: a new inhibitor of pyroglutamyl peptidase. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo). 45, 1079- 1083. Aoyagi, T., Wada, T., Nagai, M., Kojima, F., Harada, S., Takeuchi, T., Takahashi, H., Hirokawa, K. and Tsumita, T., 1990a. Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia. 46, 94-97. Aoyagi, T., Wada, T., Nagai, M., Kojima, F., Harada, S., Takeuchi, T., Takahashi, H., Hirokawa, K. and Tsumita, T., 1990b. Increased gamma-aminobutyrate aminotransferase activity in brain of patients with Alzheimer's disease. Chem Pharm Bull (Tokyo). 38, 1748-1749. Archavachotikul, K., Ciccone, T. J., Chinoy, M. R., Nielsen, H. C. and Volpe, M. V., 2002. Thyroid hormone affects embryonic mouse lung branching morphogenesis and cellular differentiation. Am J Physiol Lung Cell Mol Physiol. 282, L359-369. Arsenijevic, Y. and Weiss, S., 1998. Insulin-like growth factor-I is a differentiation factor for postmitotic CNS stem cell-derived neuronal precursors: distinct actions from those of brain-derived neurotrophic factor. J Neurosci. 18, 2118- 2128. Awade, A., Gonzales, T., Cleuziat, P. and Robert-Baudouy, J., 1992. One step purification and characterization of the pyrrolidone carboxyl peptidase of Streptococcus pyogenes over-expressed in Escherichia coli. FEBS Lett. 308, 70-74. Awade, A. C., Cleuziat, P., Gonzales, T. and Robert-Baudouy, J., 1994. Pyrrolidone carboxyl peptidase (Pcp): an enzyme that removes pyroglutamic acid (pGlu) from pGlu-peptides and pGlu-proteins. Proteins. 20, 34-51. Awouters, P., Meissner, H. P. and Henquin, J. C., 1985. Thyrotropin-releasing hormone and insulin release: in vitro studies with islets of normal and dysthyroid mice. Diabetes Res. 2, 105-110. Bajoria, R., Stagiannis, K. D. and Fisk, N. M., 1997. Effect of antenatal administration of thyrotrophin releasing hormone on f<strong>eta</strong>l flow velocity waveforms. Arch Dis Child F<strong>eta</strong>l Neonatal Ed. 77, F127-130. Baker, J., Liu, J. P., Robertson, E. J. and Efstratiadis, A., 1993. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 75, 73-82. Banda, R. W., Means, M., Fitzgerald, M. and Scherch, H., 1987. Trophic effect of thyrotropin releasing hormone on neuronal process in culture. Neurology. 37, 285-295. Banda, R. W., Means, M. and Samaha, F., 1985. Trophic effect of thyrotropin releasing hormone on murine ventral horn neurons in culture. Ann Neurol. 35, 93-97. Baquer, W. Z., McClean, P. and Greenbaun, A. C., 1978. Normal and Pathological Development of Energy M<strong>eta</strong>bolism, London. 218 Bibliografia
- Page 1 and 2:
Jakintza-arloa: Medikuntza Prolil e
- Page 3 and 4:
UNIVERSIDAD DEL PAIS VASCO Eman ta
- Page 5 and 6:
Doktore-tesia Naiara Agirregoitia M
- Page 7 and 8:
Esker onak Lan hau hasi nuenetik mo
- Page 9:
David Artola Blancoren Oroimenez Es
- Page 12 and 13:
Aurkibidea SARRERA 1.NEUROPEPTIDOAK
- Page 14 and 15:
Aurkibidea 7.4. BIRIKAK 65 7.5. GIL
- Page 16:
Aurkibidea 2.4.PIROGLUTAMIL PEPTIDA
- Page 19 and 20:
Sarrera 2 Sarrera
- Page 21 and 22:
Neuropeptidoak dira: 4 Hurrengo tau
- Page 23 and 24:
Neuropeptidoak 6 1.2.4. Askapena Ne
- Page 26 and 27:
Tirotropinaren Hormona Askatzailea
- Page 28 and 29:
Tirotropinaren Hormona Askatzailea
- Page 30 and 31:
Tirotropinaren Hormona Askatzailea
- Page 32 and 33:
Tirotropinaren Hormona Askatzailea
- Page 34:
Tirotropinaren Hormona Askatzailea
- Page 37 and 38:
Prolil endopeptidasa burututako leh
- Page 39 and 40:
Prolil endopeptidasa 22 3.3. PROLIL
- Page 41 and 42:
Prolil endopeptidasa 24 3.5. GARRAN
- Page 43 and 44:
Piroglutamil peptidasa I Mutagenesi
- Page 45 and 46:
Piroglutamil peptidasa I Katuaren g
- Page 48 and 49:
5. GARUN GARAPENA 5.1. SARRERA 5.1.
- Page 50 and 51:
Garun garapena Rhombentzefaloaren k
- Page 52 and 53:
Garun garapena mekanismoa hurrengoe
- Page 54 and 55:
Garun garapena Oinarrizko morfologi
- Page 56 and 57:
Garun garapena egunetan, baina 40.
- Page 58 and 59:
Garun garapena badaude, eta entzima
- Page 60 and 61:
Garun garapena neuronen genesia (Fr
- Page 62 and 63:
Garun garapena hipotiroideoaren adi
- Page 64 and 65:
Garun garapena azpiko zati bat. Bi
- Page 66 and 67:
Garun garapena lank., 1984; Gayo et
- Page 68 and 69:
Organo periferikoen garapena 6.ORGA
- Page 70 and 71:
Organo periferikoen garapena Peptid
- Page 72 and 73:
Organo periferikoen garapena eta la
- Page 74 and 75:
Organo periferikoen garapena Birike
- Page 76:
Organo periferikoen garapena ondore
- Page 79 and 80:
Zahartzapena Entzefalinak eta TRH-a
- Page 81 and 82:
Zahartzapena Bradikininaren hartzai
- Page 83 and 84:
Zahartzapena igoerarekin bat dator.
- Page 86 and 87:
HELBURUA
- Page 88 and 89:
HELBURUA Helburua Organismoaren haz
- Page 90 and 91:
Helburua Peptidasa solugarrien egin
- Page 92 and 93:
MATERIALAK ETA METODOAK
- Page 94 and 95:
MATERIALAK ETA METODOAK Materialak
- Page 96 and 97:
3. PRODUKTU KIMIKOAK o Azetato sodi
- Page 98 and 99:
Materialak 4.2.ENTSEIU ENTZIMATIKOE
- Page 100 and 101:
B. METODOAK 1. ANIMALIEN PERFUSIO E
- Page 102 and 103:
1. IRUDIA: Animaliaren perfusioa. M
- Page 104 and 105:
3. IRUDIA: Garunaren lehenengo ebak
- Page 106 and 107:
2. LAGINEN PRESTAKUNTZA Metodoak Au
- Page 108 and 109:
Metodoak 3.AKTIBITATE ENTZIMATIKOAR
- Page 110 and 111:
Teknika Metodoak Substratu soluzioa
- Page 112 and 113:
Metodoak Materialak eta Metodoak 95
- Page 114 and 115:
EMAITZAK Prolil endopeptidasa solug
- Page 116:
UP/mg proteina 3000 2000 1000 0 Pro
- Page 119 and 120:
Mintzari loturiko prolil endopeptid
- Page 122 and 123:
1.2. PIROGLUTAMIL PEPTIDASA I 1.2.1
- Page 124:
UP/mg proteina 5000 4000 3000 2000
- Page 127 and 128:
Mintzari loturiko piroglutamil pept
- Page 129 and 130:
Prolil endopeptidasa garapenean 112
- Page 131 and 132:
Prolil endopeptidasa garapenean ham
- Page 133 and 134:
Prolil endopeptidasa garapenean PRO
- Page 135 and 136:
Prolil endopeptidasa garapenean Kor
- Page 137 and 138:
Prolil endopeptidasa solugarria gar
- Page 139 and 140:
Prolil endopeptidasa solugarria gar
- Page 141 and 142:
Prolil endopeptidasa solugarria gar
- Page 143 and 144:
Mintzari loturiko prolil endopeptid
- Page 146 and 147:
Mintzari loturiko prolil endopeptid
- Page 148 and 149:
Mintzari loturiko prolil endopeptid
- Page 150 and 151:
Mintzari loturiko prolil endopeptid
- Page 152 and 153:
UP/mg proteina 3000 2000 1000 0 Min
- Page 154 and 155:
UP/mg proteina 500 400 300 200 100
- Page 156 and 157:
UP/mg proteina 300 200 100 0 Mintza
- Page 158 and 159:
Piroglutamil peptidasa I solugarria
- Page 160 and 161:
Piroglutamil peptidasa I solugarria
- Page 162 and 163:
Piroglutamil peptidasa I solugarria
- Page 164 and 165:
Piroglutamil peptidasa I solugarria
- Page 166 and 167:
Piroglutamil peptidasa I solugarria
- Page 168 and 169:
Piroglutamil peptidasa I solugarria
- Page 170 and 171:
Mintzari loturiko piroglutamil pept
- Page 172 and 173:
Mintzari loturiko piroglutamil pept
- Page 174 and 175:
UP/mg proteina 600 400 200 0 Mintza
- Page 176 and 177:
UP/mg proteina 400 300 200 100 0 Mi
- Page 178 and 179: UP/mg proteina 400 300 200 100 0 Mi
- Page 180 and 181: UP/mg proteina 200 150 100 50 0 Min
- Page 182 and 183: UP/mg proteina 150 100 50 0 Mintzar
- Page 184 and 185: Prolil endopeptidasa zahartzapenean
- Page 186 and 187: Prolil endopeptidasa zahartzapenean
- Page 188 and 189: Prolil endopeptidasa zahartzapenean
- Page 190 and 191: Prolil endopeptidasa zahartzapenean
- Page 192 and 193: Prolil endopeptidasa zahartzapenean
- Page 194 and 195: Piroglutamil peptidasa I solugarria
- Page 196 and 197: UP/ mg proteina 400 300 200 100 0 P
- Page 198: UP/ mg proteina 5000 4000 3000 2000
- Page 201 and 202: Piroglutamil peptidasa I solugarria
- Page 203 and 204: Piroglutamil peptidasa I solugarria
- Page 205 and 206: EZTABAIDA
- Page 207 and 208: EZTABAIDA 1. PROLIL ENDOPEPTIDASA P
- Page 209 and 210: Prolil endopeptidasa Jaio berrian e
- Page 211 and 212: Prolil endopeptidasa peptido hauek
- Page 213: Prolil endopeptidasa 1.4. PROLIL EN
- Page 216 and 217: Piroglutamil peptidasa I Lehen aipa
- Page 218 and 219: Piroglutamil peptidasa I TRH-aren e
- Page 221 and 222: Emaitzen Analisi orokorra 3. EMAITZ
- Page 223 and 224: ONDORIOAK
- Page 225 and 226: ONDORIOAK Ondorioak 1. Prolil endop
- Page 228: BIBLIOGRAFIA
- Page 233 and 234: Bibliografia Berl, S. and Clarke, D
- Page 235 and 236: Bibliografia Carr, F. E., Need, L.
- Page 237 and 238: Bibliografia de Gandarias, J. M., C
- Page 239 and 240: Bibliografia el-Dahr, S. S., 1997.
- Page 241 and 242: Bibliografia Gil, J., 1997. Ontogen
- Page 243 and 244: Bibliografia importance of cardiac
- Page 245 and 246: Bibliografia converting enzyme inhi
- Page 247 and 248: Bibliografia Lee, H. J., Sagawa, K.
- Page 249 and 250: Bibliografia Manaker, S., Eichen, A
- Page 251 and 252: Bibliografia hormone (TRH) in the p
- Page 253 and 254: Bibliografia Otto, C., Zuschratter,
- Page 255 and 256: Bibliografia Re, R. N., 2003a. Impl
- Page 257 and 258: Bibliografia Sidman, R. L., 1961. H
- Page 259 and 260: Bibliografia ten Have-Opbroek, A. A
- Page 261 and 262: Bibliografia Weil-Malherbe, H., 197
- Page 263: Bibliografia Zagon, I. S., Verderam